Related Experiment Video

Updated: May 10, 2026

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

Targeting ERBB receptors shifts their partners and triggers persistent ERK signaling through a novel ERBB/EFNB1

Paola D Vermeer1, Paul L Colbert, Bryant G Wieking

  • 1Authors' Affiliation: Cancer Biology Research Center, Sanford Research, University of South Dakota, Sioux Falls, South Dakota.

Cancer Research
|July 2, 2013
PubMed

Insights

EphrinB1 (EFNB1) interacts with the Epidermal Growth Factor Receptor (EGFR), contributing to drug resistance in head and neck squamous cell carcinoma (HNSCC). Targeting EFNB1 may overcome resistance to EGFR-targeted therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Head and neck squamous cell carcinoma (HNSCC) frequently overexpresses the Epidermal Growth Factor Receptor (EGFR/ERBB1).
  • Despite overexpression, EGFR-targeted therapies like cetuximab show limited clinical efficacy in HNSCC treatment.
  • Mechanisms underlying this therapeutic resistance require further investigation.

Purpose of the Study:

  • To investigate novel interactions involving EGFR in HNSCC.
  • To elucidate the role of EphrinB1 (EFNB1) in EGFR signaling and cetuximab resistance.
  • To evaluate EFNB1 as a potential therapeutic target in HNSCC.

Main Methods:

  • Analysis of the interaction between EGFR and EFNB1 in HNSCC models.
  • Assessment of EFNB1 phosphorylation and downstream signaling in the presence of cetuximab.
  • Evaluation of tumor growth and survival in a murine HNSCC model following EFNB1 attenuation.

Main Results:

  • A novel interaction between EGFR and EFNB1 was identified.
  • EFNB1 phosphorylation and signaling persist despite cetuximab treatment, indicating a mechanism of drug resistance.
  • Cetuximab treatment induced a shift in EGFR dimerization partners, suggesting pathway reactivation.
  • Attenuation of EFNB1 significantly slowed tumor growth and improved survival in a preclinical HNSCC model.

Conclusions:

  • EFNB1 is a component of the EGFR signaling complex in HNSCC.
  • EFNB1 signaling contributes to HNSCC development and may mediate resistance to EGFR-targeted therapies.
  • Targeting EFNB1 presents a potential strategy to overcome drug resistance in HNSCC and other solid tumors.

More Related Videos

Spatial and Temporal Analysis of Active ERK in the C. elegans Germline08:40

Spatial and Temporal Analysis of Active ERK in the C. elegans Germline

Published on: November 29, 2016

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal01:22

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...